Josh Enomoto

Josh Enomoto

InvestorPlace Contributor

Brokering multi-million-dollar deals with some of the world’s biggest companies and providing in-depth marketing analyses, Josh Enomoto takes his firsthand knowledge of the corporate boardroom and delivers them across several media outlets. In addition to his work at InvestorPlace, Josh contributes content for Benzinga, TipRanks, EmergingGrowth and Blockster. He is also a guest expert at CGTN America.

While leaving no stone unturned regarding sector coverage, Josh has written extensively about cryptocurrencies. You can follow him on Blockster, a crypto-centric social media platform and on LinkedIn.

Recent Articles

Does Sorrento Therapeutics Meet the ‘SAD’ Criteria for Vaccines?

By Josh Enomoto, InvestorPlace Contributor

If you love to gamble, SRNE stock is the right one for you. Few other companies, if any, have pivoted as hard as Sorrento did toward Covid-19. Just be aware of the risks.

7 High-Growth Value Stocks for a Post-Pandemic Future

By Josh Enomoto, InvestorPlace Contributor

Because of the unprecedented Covid-19 crisis, many discounted securities appear to be value stocks. Here are seven names that truly deserve that designation.

Driverless Tech Is Here with the Gores Metropoulos SPAC

By Josh Enomoto, InvestorPlace Contributor

Gores Metropoulos is more than just another SPAC. Via a planned reverse merger with Luminar Technologies, GMHI stock could skyrocket off the underlying autonomous vehicle technology. Just be sure to understand the science before diving in.

Political Ad Debate Is a Temporary Distraction for Facebook

By Josh Enomoto, InvestorPlace Contributor

The vitriolic political race hasn’t done any favors for Facebook stock but don’t forget that this ugly drama will eventually end.

Why Dr. Fauci Holds the Key for Edge Services Provider Fastly

By Josh Enomoto, InvestorPlace Contributor

Not surprisingly, FSLY stock tracks closely with novel coronavirus cases due to the implications of higher data services demand. Because of that, the trajectory of Fastly depends on Dr. Fauci or more specifically, whether Americans will listen to him.

Load More